MedTrace Logo

Topical Multivitamin Serum for Skin Heath

NCT07368686 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-05

No results posted yet for this study

Summary

Skin boosters are injectable and topical treatments designed to improve dermal quality and restore skin health. These products typically include hyaluronic acid formulations, biostimulatory agents, platelet-rich plasma (PRP), growth factors, and polynucleotides. Their growing use in aesthetic medicine is supported by their diverse mechanisms of action and routes of administration.

One such category of interest includes polynucleotide-based therapies, most notably Polydeoxyribonucleotide (PDRN). Derived from the DNA of salmon or trout, PDRN exhibits dual regenerative and anti-inflammatory properties. Mechanistically, it promotes tissue repair by supplying nucleotides essential for DNA synthesis and activates adenosine A2A receptors, thereby enhancing angiogenesis and mitigating inflammation. Clinically, PDRN has been applied in aesthetic medicine for skin rejuvenation, where it improves elasticity, texture, and reduces fine lines, as well as in wound healing and scar remodeling, supporting its integration into advanced bioregenerative protocols.

Among such agents, VAMP™ ADVANCED Topical Multivitamin Serum is formulated to improve hydration, elasticity, and overall skin radiance through a proprietary blend of amino acids, vitamins, and peptides. While preliminary data suggest potential benefits, robust peer-reviewed clinical studies remain limited. This study seeks to evaluate the efficacy of topical application of VAMP™ ADVANCED Topical Multivitamin Serum following microneedling in skin rejuvenation.

Conditions

  • Aesthetic

Interventions

DEVICE

Microneedeling with topical application of VAMP(TM) ADVANCED Topical Multivitamin Serum

VAMP™ Topical Multivitamin Serum is not indicated for use in pregnancy, lactation, or in individuals under the age of 22. Female participants of childbearing potential will be required to undergo urine pregnancy testing at baseline and prior to each treatment session. They will also be instructed to use an acceptable form of effective contraception for the duration of the study.

Sponsors & Collaborators

  • Erevna Innovations Inc.

    lead OTHER

Principal Investigators

  • Andreas Nikolis, MD, PhD · Erevna Innovations Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2027-02-01
Completion
2027-03-01

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07368686 on ClinicalTrials.gov